|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||
| Current Assets: | ||||||||||
| Money Market Funds (cash equivalents) | ||||||||||
| Prepaid expenses | ||||||||||
| Total current assets | ||||||||||
| Deferred offering costs | ||||||||||
| Marketable securities | ||||||||||
| TOTAL ASSETS | ||||||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||||||||||
| Current liabilities: | ||||||||||
| Accrued expenses | ||||||||||
| Amount due to Sponsor | ||||||||||
| Sponsor | ||||||||||
| Total amount due to Sponsor | ||||||||||
| Promissory note - Sponsor | ||||||||||
| Total Current Liabilities | ||||||||||
| Deferred underwriting compensation | ||||||||||
| TOTAL LIABILITIES | ||||||||||
| Ordinary shares subject to possible redemption, 1,652,509 shares (at redemption price of $11.52 and $10.82 per share) at September 30, 2026 and December 31, 2025, respectively | ||||||||||
| Shareholders’ deficit: | ||||||||||
| Ordinary shares, par value $0.0001 per share; 500,000,000 shares authorized; 2,000,900 and 2,000,900 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | ||||||||||
| Additional paid-in capital | ||||||||||
| Share capital receivable | ||||||||||
| Accumulated deficit | ||||||||||
| Total Shareholders’ deficit | ||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT |
Loading...
